Section 3 of 6
Product information and disease description
303 evidence topics · 172 sources
Product description
Phase of product development
Regulatory status: Submission planned; BLA planned, with topline pivotal interim data and FDA feedback on the submission pathway expected in the first half of 2027
Launch
No evidence found.
Development stage: dosing complete in the pivotal and ASPIRE trials
Breakthrough Therapy designation: September 2025
Regenerative Medicine Advanced Therapy designation: April 2024
Orphan drug and rare pediatric disease designations: FDA, October 2020
| Field | Quoted record |
|---|---|
| Generic name | “recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene” |
| Orphan designation | “Treatment for Rett syndrome” |
| Designation date | “10/07/2020” |
| Designation status | “Designated” |
Orphan drug designation: European Commission, September 2021
Innovative Licensing and Access Pathway designation: MHRA, February 2024
Rare pediatric disease priority review voucher eligibility
FDA interactions: written alignment on the pivotal trial design and the submission pathway
FDA interactions: chemistry, manufacturing and controls
Health Canada authorizations
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Taysha Gene Therapies
Nonproprietary name and development code
Nonproprietary name: WHO proposed International Nonproprietary Name and substance description
Brand name
No evidence found.
Therapeutic class: self-complementary AAV9 gene transfer therapy
Licensing: Abeona Rett Agreement
Licensing: patent rights in-licensed for TSHA-102
Rights to the product: Astellas option expired in October 2025
Dosage forms and strengths
Pharmaceutical form and route of administration
Dose levels administered in the clinical trials
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
WHO International Nonproprietary Name classification
FDA substance registry classification
Regulatory classification as a regenerative medicine therapy
AHFS classification
No evidence found.
Indication
Investigational status: no approved indication
Proposed indication: patients aged 2 years and older with Rett syndrome
Population studied: females with a MECP2 loss-of-function mutation
Pharmacology
Mechanism of action
Vector construct: self-complementary AAV9 encoding a miniaturized MECP2 with the miRARE element
Intended mechanism: one-time delivery of a functional MECP2 to central nervous system cells
Rationale for autoregulation: risks of MeCP2 under-expression and over-expression
miRARE: silencing in cells with normal MeCP2 function and expression in MeCP2-deficient cells
Proposed feedback mechanism: microRNA seed sequences in the 3 prime untranslated region
Self-complementary genome: a transcription-ready transgene
Transgene: truncated MECP2 retaining the methyl-CpG-binding and NCoR/SMRT interaction domains
Pharmacodynamics
Transgene and protein expression: self-complementary compared with single-stranded AAV9 in Rett model cells
Functional comparison of mini-MeCP2 and full-length MeCP2 protein
Genotype-dependent expression attributed to miRARE in Rett model cells
miRARE silencing of transgene expression in cultured cell lines
Survival, weight, and behavior after intracerebroventricular dosing in neonatal Mecp2 knockout mice
Efficacy of the human-ready construct in Mecp2 knockout mice
“In KO mice, TSHA-102 improved respiration, weight, and survival across multiple doses and treatment ages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Viral genomic DNA and miniMECP2 mRNA were present in the CNS. MiniMeCP2 protein expression was higher in the KO spinal cord compared to the brain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In female mice, TSHA-102 permitted survivals that were similar to those of vehicle-treated controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In all, these pivotal data helped to support the regulatory approval to initiate a clinical trial for TSHA-102 in RTT patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
miRARE and the safety of high-dose miniMECP2 gene therapy in Rett mice
“However, controlling deleterious overexpression of MECP2 remains the critical unmet obstacle towards a safe and effective gene therapy approach for Rett syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data provided herein show that insertion of miRARE into the miniMECP2 gene expression cassette greatly improved the safety of miniMECP2 gene transfer without compromising efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, this built-in regulation system does not require any additional exogenous drug application, and no miRNAs are expressed from the transgene cassette.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonclinical toxicology: single intrathecal dose in rats
Pharmacokinetics
Route: delivery into cerebrospinal fluid and systemic exposure
“Delivery of recombinant adeno-associated virus serotype 9 (rAAV9) into cerebrospinal fluid bypasses the blood–brain barrier and can permit efficient brain tissue transduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As with intracisterna magna (ICM) or intra-cerebroventricular (ICV) instillation, IT delivery bypasses the blood–brain barrier, reduces vector load in systemic circulation, and minimizes risk of interference of pre-existing anti-AAV antibodies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Uniquely, it offers the possibility of outpatient treatment with no specialized surgical equipment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Biodistribution of TSHA-102 in nonhuman primate brain and spinal cord after lumbar intrathecal infusion
“CNS biodistribution showed generally similar vector genome levels in all CNS tissues tested, with a low value observed at the 90-day point for the cervical spinal cord” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across four NHP biodistribution studies, at times ranging from 1 month to 1 year post-treatment, lumbar IT administration led to widespread, stable, and generally uniform vector genome levels throughout the brain and spinal cord.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across five NHP biodistribution studies, rAAV9 DNA was quantifiable in all brain and CNS tissues examined, irrespective of RoA (IT versus ICM) or time post-necropsy, at typical levels exceeding 1 vg copy per brain cell at the highest doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparison of lumbar intrathecal and intracisterna magna delivery
“At comparable doses and times, IT and ICM delivery led to widespread and consistent distribution of vector genomes, approximating 1 vg/diploid host genome throughout the brain at the higher doses tested.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ratio of ICM to lumbar IT vector biodistribution in various brain and spinal cord tissues ranged from <1 (temporal lobe) to ~5 (cerebellum).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose dependence and change over time in brain vector genome levels
“Comparing TSHA-102 versus TSHA-105 data, both with lumbar IT delivery, the four-fold increase in input dose with TSHA-105 was associated with a ~2.5-fold increase in vector genome levels detected in brain tissues; this difference was seen at both necropsy time points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis also indicated higher brain vector genome levels in Day ≥180 necropsy samples, relative to Day 90 samples, in animals that had been treated by lumbar IT dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations reported for the lumbar intrathecal route
“However, some studies have suggested the lumbar IT route leads to limited transduction of brain tissues” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The fact that these studies were conducted separately, according to different protocols, limits the precision of any quantitative claims that can be made for rAAV9 biodistribution from this data set” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration and monitoring conditions of the nonclinical biodistribution studies
“IT injection was to the L4-5 or L5-6 intervertebral space, with the needle tip angled slightly cranially.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Injections (2.5 mL total volume) were performed with animals prone or recumbent, not in the Trendelenburg position.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No immunosuppression was used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Detection of vector DNA in all tissues analyzed at 90 and 180 days
Pharmacokinetic measurements in humans
No evidence found.
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Age range of the pivotal cohort: females aged 6 to under 22 years
Children aged 5 to 8 years: REVEAL Pediatric trial
Children aged over 2 to under 4 years: ASPIRE trial
Extrapolation of efficacy to children aged 2 to under 6 years
Paediatric subsets and studies agreed in the European Union paediatric investigation plan
Sex: the trials enrolled females
Participants requiring invasive ventilatory support were excluded
Pregnancy, lactation, renal impairment, and hepatic impairment
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Lonimecgene renparvovec
Immunoprophylaxis schedule and taper in the trial protocols
Vaccination required before the immunosuppression regimen
Pre-existing anti-AAV9 antibodies in the nonclinical studies
“Serum AAV9 neutralizing (nAb) antibodies, were assessed before treatment. Animals with detectable nAbs (e.g., titers ≥1:10) were preferentially chosen for diluent-only treatment, whereas those with low or undetectable nAbs could receive rAAV9 treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical pharmacokinetic drug interaction studies
No evidence found.
Effects of Lonimecgene renparvovec on other drugs
No evidence found.
Dosing and administration
Dosage
Dose levels evaluated in the REVEAL Part A trials
Dose administered to the pivotal cohort
Dose escalation objective in the phase 1/2 trials
Administration
Pharmaceutical form and route in the European Union paediatric investigation plan
Procedure and care setting
Administration of the first dose given in the clinical program
Access and distribution
Access during development: clinical trial participation only
Commercial manufacturing and supply agreement with Catalent
Commercial-scale manufacturing process qualification
Care setting: intrathecal administration with outpatient potential
Market access and payer research
Co-prescribed/Concomitant therapies
Immunoprophylaxis given with the vector: sirolimus and oral prednisolone
Immunosuppression initiation relative to dosing
Completion of the steroid and sirolimus tapers in the first participants treated
Adverse events attributed to the immunosuppressive regimen
Antiseizure medications during follow-up
Effect of Lonimecgene renparvovec on quality measures
Product-specific effect on quality measures
No evidence found.
Product comparison
Comparator landscape as stated by the sponsor
Trofinetide: approved indication and dosing
Trofinetide: mechanism of action and tolerability
NGN-401: construct, regulation, and route of administration
NGN-401: registrational trial and expected data
NGN-401: registry record of the Embolden trial
Published comparison of TSHA-102 and NGN-401
Place of product in therapy
Disease description
Definition and etiology
Clinical definition
“Rett syndrome (RTT) is a severe, progressive, neurodevelopmental disorder, which affects predominantly females. In most cases, RTT is associated with pathogenic variants in MECP2. MeCP2, the protein product of MECP2, is known to regulate gene expression and is highly expressed in the brain. RTT is characterized by developmental regression of spoken language and hand use that, with hand stereotypies and impaired ambulation, constitute the four core diagnostic features.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical picture associated with typical RTT is defined by a regression of purposeful hand use and spoken language, with the development of gait abnormalities and hand stereotypies. After the period of regression, a stage of stabilization and potentially even improvement ensues, with some individuals partially regaining skills.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor description of the disease
Original descriptions by Rett and by Hagberg
“Rett Syndrome (RTT, MIM 312750), an X-linked neurodevelopmental condition characterized by loss of spoken language and hand use with the development of distinctive hand stereotypies, was originally described in the 1960’s by Andreas Rett” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Believing the symptoms to be consistent with a metabolic disorder, he called it ‘cerebroatrophic hyperammonaemia’ in a 1966 German publication” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-five patients, exclusively girls, from three countries had a uniform and striking progressive encephalopathy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The condition is similar to a virtually overlooked syndrome described by Rett in the German literature.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Genetic cause: MECP2 variants
“Our study reports the first disease-causing mutations in RTT and points to abnormal epigenetic regulation as the mechanism underlying the pathogenesis of RTT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using a battery of modern mutation detection assays, mutations in MECP2 can be found in 95–97% of individuals with typical RTT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, even using the best methodologies, 3–5% of individuals who strictly meet clinical criteria for RTT do not have an identified mutation in MECP2, indicating that a mutation in this gene is not required to make the diagnosis of typical RTT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The situation is more dramatic in atypical cases, with only 50–70% having identified mutations in MECP2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because MECP2 mutations are neither necessary nor sufficient to make the diagnosis of RTT, RTT remains a clinical diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MECP2-related disorders nomenclature
De novo occurrence and X-linked inheritance
Paternal origin of de novo variants and female predominance
“RTT almost exclusively affects female offspring and, in 99.5% of all cases, is sporadic and due to de novo mutations in the MECP2 gene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We analyzed the parental origin of MECP2 mutations in sporadic cases of RTT, by analysis of linkage between the mutation in the MECP2 gene and intronic polymorphisms in 27 families with 15 different mutations, and we found a high predominance of mutations of paternal origin in 26 of 27 cases (P<.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that de novo mutations in RTT occur almost exclusively on the paternally derived X chromosome and that this is most probably the cause for the high female:male ratio observed in patients with RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Males with MECP2 variants
“To enhance understanding of the phenotypic spectrum present in these individuals, we identified thirty males with MECP2 mutations in the RTT Natural History Study databases. A wide phenotypic spectrum was observed, ranging from severe neonatal encephalopathy to cognitive impairment. Two males with a somatic mutation in MECP2 had classic RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“careful review of the clinical history determined that an additional 12/28 subjects met criteria for atypical RTT, but with more severe clinical presentation and course, and less distinctive RTT features, than females with RTT, leading to the designation of a new diagnostic entity, Male RTT Encephalopathy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Rett syndrome
Australia: cumulative incidence by age, Australian Rett Syndrome Database
“the cumulative incidence was 1.09 per 10,000 females by 12 years of age. The cumulative incidence by the age of 5 years increased from .39 per 10,000 in the 1980 to 1984 cohort to .76 per 10,000 in birth cohorts beyond 1984.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Australia: cumulative risk of diagnosis and birth prevalence, females born 1976 to 2006
“The population-based Australian Rett Syndrome Database was used to identify a total of 349 verified Rett syndrome females born 1976-2006 and diagnosed 1982-2008.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cumulative risk of diagnosis had almost doubled by 32 y of age [1/8,905 or 11.23 per 100,000 person-years (95% CI, 10.03–12.45)] in comparison with 5 y of age [1/15,361 or 6.51 per 100,000 person-years (95% CI, 5.65–7.39)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The birth prevalence varied by birth year (Table 2), peaking for those born in the early to mid 1990s.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Year of birth | Number of cases | Number of cases per 100,000 female births (95% CI) |
|---|---|---|
| Overall (1976-2006) | “349”View highlighted excerpt for this quote | “9.37 (8.41-10.41)”View highlighted excerpt for this quote |
France: incidence of Rett syndrome with an MECP2 variant
“The present study, based on a large cohort of 424 patients with Rett syndrome, found that the incidence of this disease with a MECP2 mutation varied between 0.43 to 0.71 per 10,000 females.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Given that this is a minimum incidence because complete inventory was not possible, this study of patients with Rett syndrome reinforces the fact that the great majority of patients with Rett syndrome have a MECP2 mutation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: annual incidence of diagnosis in claims data, 2018 and 2019
“Overall, the annual incidence of RTT in this dataset was an estimated 0.34 and 0.23 per 10,000 enrollees in 2018 and 2019, respectively (Table 2). Among female patients, the annual incidence was 0.43 and 0.31 per 10,000 female enrollees in 2018 and 2019, respectively, while among male patients, it was 0.22 and 0.13 per 10,000 male enrollees, respectively. Stratified by age, incidence estimates per 10,000 enrollees for the pediatric population in 2018 and 2019 were 1.40 and 1.25, respectively, for ages 0–4 years; 1.53 and 0.92 for ages 5–10 years; and 1.00 and 0.67 for ages 11–17 years (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual incidence was calculated as the proportion of patients newly diagnosed with RTT among the total number of at-risk patients at the start of the study period. A minimum 6-month washout period was used to ensure at-risk enrollees and incident cases did not have a RTT diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canada: incident cases in Ontario administrative data, 2017 to 2023
“Incident cases were identified between September 2017 and August 2023, while prevalent cases were captured from April 2002 to August 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From September 2017 to August 2023, 57 incident cases and 257 prevalent cases were reported in Ontario.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Rett syndrome
Global pooled prevalence in females: systematic review and meta-analysis
“We conducted a search of PubMed, Embase, Web of Science, Cochrane Library, LILACS, and LIVIVO to retrieve studies published in English between Jan. 1, 2000, and June 30, 2021. Pooled prevalence with a 95% confidence interval (CI) was estimated using a random-effects meta-analysis based on a generalized linear mixed model with a logit link.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ten eligible studies were identified (all in females), with a combined sample size of 9.57 million women and 673 Rett syndrome cases. The pooled prevalence estimate (random effects) was 7.1 per 100,000 females (95% CI: 4.8, 10.5, heterogeneity p < 0.001). Despite greatly variable precision of estimation, all estimates were compatible with a prevalence range of approximately 5 to 10 cases per 100,000 females based on their respective 95% CIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Study-specific prevalence estimates per 100,000 females (95% CI) ranged from 0.0 (0.0, 8.8) to 38.3 (4.6, 138.0), with a highly significant heterogeneity test (p < 0.001, I2 = 0.831).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No studies that included patients with RTT older than 35 years were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide prevalence per female births: reference estimates
Australia: point prevalence by age group
“The point prevalence of RTT in Australia on the 31st June 2009 was 8.6 per 100,000 females (95% CI 7.4-10.1) aged five to 18 years and 5.8 per 100,000 females (95% CI 4.8-6.9) aged 19 years to 32 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serbia: prevalence in females younger than 19 years
United States: annual prevalence of diagnosis in claims data, 2016 to 2019
“The annual prevalence of RTT between November 1, 2016 and October 31, 2019 in this dataset ranged from 0.30–0.32 per 10,000 enrollees overall, with higher prevalence ranges observed among female than male patients (female: 0.45–0.52; male: 0.08–0.10; Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual prevalence was calculated as the proportion of patients with a diagnosis of RTT among the total number of patients enrolled in the IQVIA Dx and LRx databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States, European Union, Japan, Canada, and Israel: trofinetide manufacturer estimates
United States, European Union, and United Kingdom: TSHA-102 sponsor estimate of the addressable population
Canada: estimated and diagnosed prevalence
Natural history, survival, and mortality
Natural history: age at regression and onset of hand stereotypies
“Age at onset of regression (Table 1A) occurred between 12 and 30 months in more than 80% of individuals, with 36.2% occurring between 12 and 18 months of age and 46.1% between 18 and 30 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stereotypies (Table 1B) began most frequently (55.6%) at 18–36 months, whereas 22.7% developed these from 12 to 18 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: trajectory of skill gain, loss, and regain
“Loss of previously gained skills occurred in all skill domains, with highest frequency in fine motor and expressive language domains. For most skills, loss occurred early in life and within 2 years of gain, except for loss of gross motor skills which occurred at older ages and further from age of gain. Regain of lost skills was infrequent for most skills, occurred mainly before 6 years old, and within 2 years of loss. After 6 years old, the incidence of either gaining or regaining skills was low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median age of skill loss was 3 years old or less for 46 of the 51 developmental skills (90%), and in 31 developmental skills, 95% of participants lost skills by 6 years old.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After age 6 years it is unlikely that a skill not previously obtained will be gained or that a skill previously lost will be regained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: course in women aged 40 years and older
“Information was available on 30 women with a clinical diagnosis of Rett syndrome (RTT), of whom 24 were < 50 years. Twenty‐nine women were diagnosed with classic RTT and one with atypical RTT. Of 18 women tested for MECP2 mutations, pathogenic variants were identified in 14. There was little increase in severity over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some features of RTT improved with aging, for example, epilepsy, agitation, sleep, and hand stereotypies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival: North American database of 1928 individuals
“Earlier decennial cohorts had better survival than recent cohorts, most participants surviving into middle age. Comparing overall survival between typical and atypical RTT, those with typical RTT had greater mortality than those with atypical RTT across the observed lifespan (p<.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among all participants studied, a total of 305 deaths (15.8%) had occurred as of January 1, 2006.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival: US Rett Syndrome Natural History Study
“Among 1189 valid participants, 51 died (range 3.9–66.6 years) during the 9-year follow-up period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Survival for classic and atypical RTT was greater than 70% at 45 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We can estimate, with 95% confidence, that at least 95% of the classic RTT population survive until age 20, 80% survive until age 35, and over 70% survive until age 50.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival: Australian Rett Syndrome Database, 20 years of follow-up
“Using the Kaplan-Meier method, we estimated survival of individuals registered with the Australian Rett syndrome Database (ARSD) who had been followed for up to 20 years (n = 396).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The conditional probability of survival was 77.6% (95% confidence interval (CI) 71.3, 82.8) at 20 years, 71.5% (95% CI 64.6, 77.3) at 25 years and 59.8% (95% CI 49.3,68.8) at 37 years (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival: Rett's original Austrian cohort compared with the Australian database
Causes of death
“Most deaths were due to cardiorespiratory issues. Only one died due to severe malnutrition, scoliosis, and extreme frailty.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post-operative complications were a cause of death in a minority, following scoliosis surgery, ileostomy, and tonsillectomy. Epilepsy was cited as cause of death (without respiratory complications) in four classic RTT participants and one atypical RTT participant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Information on cause of death was available for 57 (82.6%) out of 69 females who were deceased. Lower respiratory tract infection (36.8% 21/57) was the most common cause of death, followed by aspiration/asphyxiation (31.6% 18/57), respiratory failure (14.0% 8/57) and seizure related illness (5.3% 3/57).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sudden death: cardiorespiratory and autonomic risk factors
“Notably, cardiorespiratory dysfunction may account for 26% to 47% of sudden, unexpected Rett syndrome-associated deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following a review of the articles relating to sudden death, we identified reduced heart rate variability, epilepsy and deleterious changes in cardiac repolarization (QT prolongation and T-wave changes) as potential risk factors for sudden death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors for mortality: severity, ambulation, weight, seizures, and genotype
“For classic RTT, several variables, such as ambulation, frequent seizures, frequent hospitalizations and illness, microcephaly and low weight, were independently associated with higher odds of mortality using a Cox proportional hazard model (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the majority of those who died (54%, or 19/35) weighed less than the 25th percentile on the Rett-specific charts, compared to 22% of those who survived (p < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using the Cox proportional hazard model, those with large deletions had, at any time during the observation period, slightly more than 3 times (HR 3.11, 95% CI 0.60, 16.10) the risk of death than those with the p.Arg133Cys mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
MeCP2 expression in the nervous system
“MeCP2 is an abundant nuclear protein that was originally identified in a screen for proteins with methyl-DNA-specific binding activity. It is ubiquitously expressed throughout all human tissues, but is particularly abundant within neurons” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the central nervous system (CNS), MeCP2 is expressed at low levels prenatally, but progressively increases during neuronal maturation and synaptogenesis reaching its peak in mature, post-migratory neurons, suggesting a role for MeCP2 in maintaining neuronal maturation, activity and plasticity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MeCP2 as a transcriptional regulator
“These findings have led to a model wherein MeCP2 serves as a bridge between methylated DNA and the corepressor complex, anchoring the NCoR1/SMRT complex to DNA via its NID and MBD, respectively. It is hypothesized that disruption of this bridge leads to histone hyperacetylation and an open chromatin state, thereby increasing the transcription of target genes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Loss of function and location of pathogenic variants
Neuropathology: reduced brain and neuronal size without neuronal death
“Studies employing neuroimaging, neuropathology, neurochemistry and animal models show reductions in brain size and global decreases in neuronal size, as well as alterations in multiple neurotransmitter systems.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reduced brain volume is largely due to small neuronal body size and a denser packing of cells, particularly in layers III and V of the cerebral cortex, thalamus, substantia nigra, basal ganglia, amygdala, cerebellum and hippocampus” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients also have reduced dendritic arborization, indicative of a delay in neuronal maturation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neuronal and glial cell types affected
“Cortical GABAergic neurons exhibit approximately 50% higher MECP2 expression level than non-GABAergic neurons, suggesting that MECP2 deficiency has a more significant effect on GABAergic neurons than on other neurons” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MECP2 deficiency in GABAergic neurons leads to the loss of multiple functions such as social behavior, learning, memory, motor function, stereotyped behaviors, and sensorimotor gating.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
X-chromosome inactivation and cellular mosaicism in females
“Female heterozygous RTT patients are mosaic, allowing some cells to express the mutant MECP2, while the others express the wild-type allele. XCI can be skewed preferentially so the mutant X chromosome is more or less expressed than the wild type, resulting in either a relatively more severe or milder presentation of RTT, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because the MECP2 gene is subject to X‐chromosome inactivation (XCI), factors including MECP2 genotypic variation, tissue differences in XCI, and skewing of XCI all likely contribute to the clinical severity of individuals with RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average XCI ratio in probands was slightly increased compared to their unaffected mothers (73% vs. 69%, p = .0006). Among the duos with informative XCI data, the majority of individuals with classic RTT had their paternal allele preferentially inactivated (n = 180/220, 82%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MECP2 genotype and clinical severity
“Participants with the R133C mutation are less severely affected than those with R168X or large DNA deletions (p<0.05). Likewise, individuals with the R168X mutation are more severely affected than those with R294X and late carboxy-terminal truncating mutations (p<0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with R168X are less likely to walk (p=0.008), retain hand use (p=0.002), or use words (p=0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using a database of 1052 participants assessed over 4940 unique visits, the largest cohort of both typical and atypical RTT patients studied to date, we examined the relationship between MECP2 mutation status and measures of growth, motor coordination, communicative abilities, respiratory function, autonomic symptoms, scoliosis, and seizures over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, p.Arg106Trp, p.Arg168X, p.Arg255X, p.Arg270X, Splice Sites, Large Deletions, Insertions, and Deletions were significantly more severe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, clinical severity continues to become progressively worse with advancing age regardless of initial severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reversal of the phenotype after MeCP2 restoration in mice
“Using a mouse model, we demonstrate robust phenotypic reversal, as activation of MeCP2 expression leads to striking loss of advanced neurological symptoms in both immature and mature adult animals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By contrast, five out of six symptomatic Stop/y,cre animals were rescued by TM treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MECP2 dosage sensitivity
“Activation of Mecp2 in Stop/y,cre males at this stage (bracket TM-1, Fig. 2A), prior to symptom onset, revealed toxicity associated with abrupt Mecp2 reactivation as 9 out of 17 mice developed neurological symptoms and died soon after the daily TM injection series” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The toxic effects resembled those caused by over-expression of an Mecp2 transgene in mice” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The intersection of MDS and RTT is best described as a ‘Goldilocks paradigm’” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in which too much of MeCP2 (MDS) and too little (RTT) will result in a severe disease state and highlights the importance of regulating this multi-functional protein and the difficult task of potential therapeutic strategies in maintaining a narrow range of MECP2 levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Clinical diagnostic criteria: 2010 consensus criteria for typical and atypical Rett syndrome
“We limited the necessary criteria to the presence of regression plus four main criteria that are absolutely required for the diagnosis of typical RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In these new criteria, history of regression and ALL of the necessary and exclusion criteria MUST be met to make the diagnosis of typical RTT, without exception.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we state that for the diagnosis of atypical RTT an individual MUST have a period of regression followed by recovery or stabilization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Young children: provisional diagnosis before regression is evident
“Because MECP2 mutations are now identified in some individuals prior to any clear evidence of regression, the diagnosis of” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RTT should be given to those individuals under 3 years old who have not lost any skills but otherwise have clinical features suggestive of RTT. These individuals should be reassessed every 6–12 months for evidence of regression. If regression manifests, the diagnosis should then be changed to definite RTT. However, if the child does not show any evidence of regression by 5 years, the diagnosis of RTT should be questioned.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Validation of the criteria in the US Natural History Study: 819 participants
“The present analysis was conducted on 819 participants enrolled as of February 28, 2010, to assess the recently modified clinical criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 765 females fulfilling criteria for classic or variant RTT, 653 (85.4%) were diagnosed as classic and 112 (14.6%) were classified as variant. A mutation was identified in 95% of 653 females with classic and 73.2% of 112 females with variant RTT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Abnormal deceleration in the rate of head growth was noted in 82%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For classic RTT, these core criteria are sufficient for diagnosis as none of the eight 2002 supportive criteria is noted uniformly. For variant RTT, diagnosis requires application of both main (2 of 4) and supportive (5 of 11) criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic testing: MECP2 sequencing with deletion and duplication analysis
“For suspicion of RTT, MECP2 gene sequencing and MLPA testing are recommended. MLPA testing is needed to detect deletions otherwise missed by sequencing; this test is necessary if no abnormalities are found by sequencing. Referral to a geneticist or genetic counsellor is recommended to review recurrence risks and answer related questions. Genetic testing results are essential for enrolment in clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Complete genetic testing involves sequencing and methods to detect larger deletions (eg, multiplex ligation-dependent probe amplification) of the MECP2 gene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, thorough and complete genetic testing for mutations in MECP2 should be performed on all participants. This would include sequencing of the coding region as well as methods such as MLPA, quantitative PCR, microarray methods, or Southern blotting to detect large DNA rearrangements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic testing: diagnostic yield of next-generation sequencing in 1,577 patients with a Rett-like presentation
“We studied 1577 patients with RTT-like clinical diagnoses and reviewed patients who were previously studied and thought to have RTT genes by Sanger sequencing. Genetically, 477 of 1577 patients with a RTT-like suspicion have been diagnosed. Positive results were found in 30% by Sanger sequencing, 23% with a custom panel, 24% with a commercial panel and 32% with whole exome sequencing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic testing: missed variant after repeated sequencing
“Here, we describe a young woman with clinically diagnosed Typical RTT syndrome who lacked a genetic diagnosis despite 20 years of investigation and multiple rounds of sequencing the MECP2 gene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This case illustrates the evolving landscape of genetic testing technologies and the limitations of Next Generation (NextGen) sequencing due to deletions, duplications and insertions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at diagnosis: US Natural History Study, 1,085 participants
“Among 919 classic and 166 atypical RTT participants, median diagnosis age was 2.7 years (interquartile range 2.0–4.1) in classic and 3.8 years (interquartile range 2.3–6.9) in atypical RTT. Pediatricians made the diagnosis of classic RTT rarely (5.2%); however, proportion diagnosed by pediatricians increased since 2006.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“33% with microcephaly before 2.5 years were diagnosed after the median age of 2.7 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at diagnosis: international caregiver survey, 756 caregivers
Age at diagnosis: trends and predictors of delay in Australian and international registries
“The median age of Rett syndrome diagnosis decreased from 4.5 years if diagnosed before 2000 to 3.5 years if diagnosed after 1999.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 909 cases were included. An older age of diagnosis was associated with later loss of hand function and speech, later onset of hand stereotypies and the presence of the p.R133C or p.R294X MECP2 mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cases with a p.R133C mutation (adjusted mean 76.5 months) and those with a p.R294X mutation (adjusted mean 69.6 months) had a later age of diagnosis compared to those with a p.T158M mutation (adjusted mean 50.5 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Multisystem involvement: prevalence of comorbidities by organ system
“Neurological comorbidities had the highest prevalence, occurring in nearly all individuals with gastrointestinal and orthopaedic concerns almost as prevalent as neurological. With the exception of low bone mineral content which was relatively common, endocrine comorbidities were seen in only around one-third of patients. Although more prevalent compared with the general population, cardiac conduction abnormalities were the least common comorbidity in RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 6253 records screened, 148 studies met inclusion criteria, spanning 24 countries and participants aged 7 months to 37 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Epilepsy prevalence ranged from 15.0% to 91.0%, scoliosis 8.9–100% and gastrointestinal dysfunction was common, including constipation (16.4–82.8%) and gastroesophageal reflux (15.8–100.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Motor symptoms: loss of purposeful hand use
“Following the initial regression period, hand function continues to decline across the age spectrum in individuals with RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conversely, more than 70% of individuals had delays in ambulation (Table 2C) and nearly 100% had abnormalities in hand function (Table 2D), both in keeping with two of the four main diagnostic criteria for classic RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Motor symptoms: hand stereotypies
“HS were reported in 922 participants with classic RTT (100%), 73 with atypical severe RTT (97.3%), 74 with atypical mild RTT (96.1%), and 17 females with MECP2 mutations without RTT (34.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While hand function decreased over time, prevalence and frequency of HS remained relatively unchanged and high.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Motor symptoms: gait impairment and loss of ambulation
Motor symptoms: dystonia, rigidity, and other movement abnormalities
“Outside of the repetitive hand movements that are part of the main diagnostic criteria of typical RTT, additional movement abnormalities are found in 60%–80% involving varying combinations of dystonia, tremor, myoclonus, chorea and progressive limb rigidity with bradykinesia resembling parkinsonism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Communication symptoms: loss of spoken language and impaired nonverbal communication
“Nearly all participants had delays in language development (Table 2F) and 90% had abnormalities in nonverbal communication (Table 2G), again reflecting significant difficulties in one of the main diagnostic features for classic RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of participants who lost previously gained skills ranged from 6.6% (Lift Head) to 88.6% (Words with Meaning).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, within expressive language, nearly all participants gained early skills such as Cooing and Babbling, but less than 25% gained Spoken Phrases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cognitive symptoms: intellectual disability
Neurological symptoms: epilepsy
“While point prevalence of active seizures ranged from 30% to 44%, the estimated cumulative lifetime prevalence of epilepsy using Kaplan-Meier approached 90%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 360 (60%) were reported to have seizures, including 315 (60%) classic and 45 (61%) atypical RTT. Physician assessment of the 602 indicated that 48% had seizures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A significant age impact for seizures was seen and seizures were infrequent before age 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Autonomic symptoms: awake breathing abnormalities
“Participants with classic or atypical severe RTT were more likely to have breathing dysfunction (nearly 100% over the lifespan) compared to those with atypical mild RTT (60-70%). Remission was common, lasting 1 year on average, with 15% ending the study in terminal remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiac signs: QTc prolongation
“Of the 613 participants with classic and atypical RTT who had EKG data, 18% had a borderline and 10% had an abnormal QTc interval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gastrointestinal symptoms: constipation, reflux, and biliary disease
“In addition to the highly prevalent neurodevelopmental issues, gastrointestinal and orthopaedic comorbidities are both also quite prevalent, each reported in over 80% of individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The gastrointestinal issues primarily involve constipation but around 40% also have gastro-oesophageal reflux.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GI manifestations affected 43.0% of 5940 patients, with increased prevalence in pediatric patients (45.6%) relative to adult patients (40.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, the prevalence of GI manifestations was likely underestimated in this study, as only those symptoms which resulted in a healthcare encounter were captured.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral and feeding symptoms: swallowing dysfunction and drooling
“Impaired swallowing function has equal prevalence to epilepsy over the lifespan but becomes apparent at a younger age often manifesting in early childhood as prolonged feeding times, choking/gagging on food and/or aspiration of liquids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among eight studies which reported on dysphagia and chewing problems, the prevalence ranged from 23.5% to 76.7%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drooling was also reported in five studies ranging from 39.2% to 92.9% among the patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Growth: deceleration of head growth and somatic growth failure
“Mean growth in classic RTT decreased below that for the normative population at 1 month for head circumference, 6 months for weight, and 17 months for length. Mean BMI was similar in those with RTT and the normative population. Pubertal increases in height and weight were absent in classic RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine signs: altered pubertal timing
Sleep symptoms: sleep disturbance and sleep-disordered breathing
Behavioral symptoms: anxiety and internalizing behavior
“Most participants with RTT (77.5%) had at least occasional anxious or nervous behavior.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Behaviour disturbances occur in nearly all individuals with RTT across the lifespan with internalising behaviours such as anxiety or mood swings being much more common overall than externalising behaviours such as aggression, hyperactivity or self-injury which are seen in about 40% of individuals, almost always with onset before 3 years of age and which improve over time in contrast to the internalising behaviours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pain: frequency, sources, and expression
“Of the 44 families responding to the survey, 24% reported that their child had experienced pain on 8 or more days (> 1 week) in the previous 30 days (43% were unsure)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ninety percent of the individuals reported on with RTT did not use words for pain. The most frequent form of pain communication was facial expression (85%) and vocalization (82%, e.g., moan, cry).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most commonly reported pain source was gastrointestinal [GI] (66%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Orthopaedic signs: scoliosis, hip displacement, and foot deformities
“This meta-analysis found that approximately two in three girls with RTT develop scoliosis, one in two exhibit foot deformities and one in three experience hip displacement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although scoliosis (Table 2E) was absent in greater than 50%, the appearance of abnormal curvature in nearly 35% as well as the evidence of surgical correction in 11.8% indicated nearly half having significant difficulties with spinal deformity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Health status in adulthood: mobility, scoliosis, epilepsy, and gastrointestinal problems
“The median age of the combined cross-sectional cohort was 25 years (range 18 to 54 years), the majority (71%) were living in their parental home and the remainder being cared for in group homes or other institutions. Just over half walked either independently (18%) or with assistance (43%). The majority (86%) had scoliosis with 40% of those having undergone corrective surgery. Almost two-thirds (64%) of the women were taking anti-epileptic medications at the time of data collection. Constipation was highly prevalent (83%) and many experienced bloating (53%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sleep disturbance was relatively common (63%), and adverse mood events and anxiety were slightly more prevalent in those aged 26-30 years in comparison to the younger and older age groups. Other frequently reported medical conditions included urinary tract infections, pneumonia and other respiratory conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Scoliosis: progression to severe curves and spinal surgery
“913 females with classic RTT were included. Scoliosis frequency and severity increased with age. Severe scoliosis was found in 251 participants (27%), 113 of whom developed severe scoliosis during the follow-up assessments. 168 (18%) had surgical correction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of the actual age distribution for the 168 participants who had surgical correction, the majority (86%) occurred between age 9 and 15, the median age was 12 years (min=5, max=21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gross motor decline in adolescence and adulthood
“here we demonstrate that slow loss of gross motor skills occurs during Stage III.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included 24 individuals aged 30-66 years at last visit after a follow-up period of 6-12 years. Results showed a clinically observable and significant decline in gross motor skills using the Rett syndrome Gross Motor Scale (RSGMS) with a tendency of less decline in the individuals with the best motor abilities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Decline in RSGMS score was associated with the presence of epilepsy and severe scoliosis that had been conservatively managed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of those 26 women walking after their childhood regression, two (8%) permanently lost their ability to walk in their 20s and nine (37.5%) of those still walking in their 40s lost that ability during their 40s or 50s.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bone health: low bone mass and fractures
“however individuals as young as three and four years of age had low BMC and aBMD values in the lumbar spine” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The fracture incidence in an Australian RTT population was shown to be 43.3 per 1000 person years, which equates to a rate nearly four times that of the general population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Respiratory complications: aspiration, lower respiratory tract infection, and respiratory failure
“Of the 1,994 with RTT, 7.27% (n = 145), 9.48% (n = 189), and 10.08% (n = 201) experienced post-index aspiration, LRTI, and RF, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of eligible individuals, 25 (28.1%) were aspiration cases. The cumulative rate of RF among RTT individuals with and without aspiration was 60.0% and 6.3%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aspiration cases were more likely to have LRTI (50% vs. 5.0%) and ≥ 1 inpatient admissions than non-aspiration controls (75.0% vs. 35.0%) (all p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epilepsy: course across the lifespan
“Three distinct patterns of seizure prevalence emerged in classic Rett syndrome, including those who did not have seizures throughout the study, those who had frequent relapse and remission, and those who had relentless seizures. Although 248 of those with classic Rett syndrome and a history of seizures were in terminal remission at last contact, only 74 (12% of those with a history of epilepsy) were seizure free and off anti-seizure medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seizures were reported for 18 of 30 women (60%) at some stage during their lives. Ten (33%) had epileptic seizures in middle age, usually generalised tonic–clonic (GTC) or myoclonic seizures, with the seizures being well controlled on medication in nine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Rett syndrome
Humanistic burden and health-related quality of life
Child health-related quality of life: CHQ-PF50 in the US Natural History Study
“More than 200 participants from 5 to 18 years of age with classic RTT finished their 2-year follow-up at the time of analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each CHQ-PF50 domain score was compared with the standard US girl score reported in the QOL manual. All scores other than those for Behavior and Family Cohesion were significantly lower than those from standard US girls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Severe clinical impairment was highly associated with poor physical QOL, but worse motor function and earlier age at onset of RTT stereotypies were associated with better psychosocial QOL; conversely, better motor function was associated with poorer psychosocial QOL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Child quality of life and family functioning: PedsQL in 23 families in Poland
“We included 23 parents of children with RTT. In this study, we used the PedsQL™ Family Impact Module, the Pediatric Quality of Life Inventory 4.0 generic core scales (PedsQL™ 4.0), and an author-designed questionnaire to assess QoL and family functioning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“QOL in children with RTT, as perceived by their parents, is reduced. RTT has a significant negative correlation with family functioning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver health-related quality of life: SF-36v2 in the US Natural History Study
“Caretaker physical component scores (PCS) were higher than mental component scores (MCS): 52.8 (9.7) versus 44.5 (12.1). No differences were noted between the baseline and 5-year follow-up. In univariate analyses, disease severity was associated with poorer PCS (p=0.006) and improved MCS (p=0.003). Feeding problems were associated with poorer PCS (p=0.007) and poorer MCS (p=0.018).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PCS and MCS scores of 35-44 year old females from the United States general population are 51.6 (8.6) and 47.8 (10.4) respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For caretakers of those with RTT, this demonstrates similarity of PCS to the general population, but lower MCS scores at 44.6 (12.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver health utility: EQ-5D-5L and CarerQol-7D in 37 UK caregivers
Parenting stress: Parenting Stress Index in 35 caregivers
“A majority (60%) of parents reported stress in the clinical range on at least one subscale of the Parenting Stress Index – Short Form. Seizures and uncertainty about their daughter’s gastrointestinal pain experience were significantly associated with higher levels of parenting stress.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of illness: disorder-specific caregiver survey of 756 caregivers in the USA, Europe, and Australia
“The questionnaire was administered anonymously online to an international sample of 756 caregivers (predominantly parents) of girls and women with RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was variability in reported frequency of problems, with the most prevalent, severe and impactful being those related to the core features of RTT (i.e., communication and fine and gross motor impairments).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ANOVAs showed that many problems had disproportionately greater impact than severity, either on affected individuals (e.g., hand stereotypies) or their caregivers (e.g., sleep difficulties, seizures, pain, and behavioral abnormalities).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a wide range of frequency of problems, from ~ 35% for hyperventilation to 99% for impairments in self-care activities of daily living. Core features or impairments were present in 70–98% of affected individuals, while other problems were more variable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver priorities: top concerns in the US Natural History Study, 925 caregivers
“Caregivers of participants enrolled in the US Natural History Study of RTT and RTT-related disorders (n = 925) were asked to identify the top 3 concerning problems impacting the affected participant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The top caregiver concerns for classic RTT were effective communication, seizures, walking/balance issues, lack of hand use, and constipation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Symptoms with severe impact on quality of life: TSHA-102 sponsor caregiver survey, 323 caregivers in four countries
“This work was funded by Taysha Gene Therapies, Inc., in accordance with Good Publications Practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 323 caregivers from the USA (n = 85), the UK (n = 115), Canada (n = 45), and Israel (n = 78) participated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Symptoms that were most commonly reported as having a severe impact on quality of life (QoL) included loss of speech (81%, n = 261), loss of purposeful hand use (80%, n = 259), loss of independent walking (61%, n = 198), loss of mobility (59%, n = 189), and involuntary hand movements (57%, n = 184).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over three-quarters of respondents (76%, n = 245) indicated that ≥ 1 new or newly challenging symptom had emerged in the 2 years prior to the survey, the most common of which was the loss of mobility, reported by 63% of caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Impact on daily activities: caregiver diaries in eight European countries
“Sixty caregivers across eight countries completed five-day diaries, and thirty participated in in-depth interviews.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Daily activities were heavily affected, with symptoms impacting 59% of activities for children, 61% for adolescents, and 38% for adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care coordination and caregiver stress: parent survey in Italy
“The data refers to 52 patients, all females, with a median age of 15 years at the time of the survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study shows that caregivers of RS patients take over most obligations and burdens by increasing their perceived level of stress. For the majority of patients, the most frequent complications were not followed by the reference subspecialist, with the only exception of epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient health utility: utility weights derived from the Rett Syndrome Behaviour Questionnaire
Economic burden and healthcare resource utilization
US claims, 5,940 females: all-cause and Rett-related healthcare resource utilization
“Among 5,940 female patients (pediatric: 3,078; adult: 2,862) with mean observation period of 2.04 years, the most prevalent clinical manifestations were neurological disorders (72.8%), gastrointestinal/nutritional disorders (41.9%), and orthopedic disorders (34.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence rate of all-cause HRU by place of service among female patients with RTT was 44.43 visits PPPY during the observation period, primarily driven by home/hospice care (16.31 visits PPPY), OP visits (9.58 visits PPPY), and therapeutic service visits (7.26 visits PPPY; Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause HRU largely comprised of RTT-related HRU, with 47% of the all-cause incidence rate attributed to a RTT diagnosis in the overall study population (Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Trends were similar by subgroup; although, rates of HRU were generally higher among pediatric patients relative to adult patients (all-cause: 52.43 and 35.86, respectively), which translated into higher mean healthcare costs (all-cause: $45,718 and $34,548, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US claims, 5,940 females: all-cause and Rett-related healthcare costs
“Mean all-cause healthcare costs were $40,326 per-patient-per-year, with medical costs driven by home/hospice care visits, therapeutic services, outpatient visits, and inpatient visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RTT-related healthcare costs comprised 45% of all-cause healthcare costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the observation period, female patients with RTT incurred mean all-cause total healthcare costs of $34,772 (86%) in pre-adjudicated medical costs and $5,554 (14%) in adjudicated pharmacy costs (Table 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean all-cause medical costs were primarily driven by home/hospice care visits ($12,054), followed by therapeutic services ($7,071), OP visits ($6,791), and inpatient visits ($6,088) among the overall cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean RTT-related total healthcare costs PPPY included $14,643 in pre-adjudicated medical costs and $3,428 in adjudicated pharmacy costs (Table 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were inflation-adjusted to 2021 US dollars (USD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US claims, 5,940 females: data source and cost limitations
“Administrative healthcare claims data from the IQVIA™ Medical Claims Data (Dx) and Longitudinal Prescription Data (LRx) databases (11/1/2016–10/31/2019) were used to address the study objectives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis relied on pre-adjudicated medical claims from IQVIA Dx database, for which payment amounts have not yet been finalized and are often inflated compared to their adjudicated equivalent. Therefore, healthcare costs may be overestimated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, overall coverage of institutional claims is lower than that of OP claims in the IQVIA Dx database, potentially resulting in incomplete capture of inpatient, ED, and long-term care/skilled nursing facility visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US claims, 5,940 patients: cost of gastrointestinal manifestations
“Mean medical costs of managing GI manifestations amounted to $4473 per patient per year (PPPY) and were somewhat higher in pediatric ($5530 PPPY) than adult ($3341 PPPY) patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GERD was associated with the highest mean medical cost ($2630 PPPY), of which the largest component was the cost of therapeutic services (including physical therapy, hydrotherapy, occupational therapy, speech therapy, and feeding assistance), which amounted to $1071 PPPY (SD: $8264).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second most costly manifestation to manage was constipation ($923 PPPY), which mean cost PPPY was higher in pediatric than adult patients ($1010 vs $830, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean medical costs were reported per patient per year (PPPY) to account for varying lengths of follow-up and inflation-adjusted to 2021 US dollars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Australian population: health sector costs converted to US dollars
“While we have identified no studies reporting specifically on the costs of managing GI manifestations in RTT, in an analysis of the Australian Rett Syndrome Database, mean healthcare costs associated with RTT management overall were estimated at AUD 21,158 PPPY (equivalent to USD 25,691 as of December 2022 [14,15]), and ranged from AUD 238 to AUD 85,776 (equivalent to USD 289 to USD 104,151 [14,15]) [16], also suggesting substantial between-patient variability in the healthcare costs incurred.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US Natural History Study registry, 455 females: hospital and emergency room visits and gastrostomy
“Over a median follow-up period of 4 years, nearly half (44.6%) of all individuals had a hospital or emergency room visit (Fig. 2), with a significantly higher proportion of visits observed in individuals with classic RTT than atypical RTT (47.1% vs. 20.9%, p = 0.001), and pediatric individuals than adult individuals (48.5% vs. 29.3%, p = 0.001) (Supplementary Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incident g-tube surgeries were observed among 13.7% of individuals, and pediatric individuals had a significantly higher incidence of g-tube surgery than adult individuals (16.7% vs. 2.7%, p = 0.002) (Supplementary Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ontario, Canada, population data: healthcare touchpoints
“In total, 246 RTT cases were indexed; 40% from central Ontario, 95% female, median age 21 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients had at least one outpatient visit (primary care 96.7%, specialist 86.6%), emergency department visit (76.8%) and inpatient hospitalization (54.5%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the 5-year follow-up period, most cases (95.1%) had at least one public claim for all-cause medication.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Epilepsy: emergency department visits and inpatient admissions at a US Rett center
“In this analysis, 98 individuals with RTT were included: 71 (72%) had epilepsy of which 33 (46%) had severe epilepsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparing all-cause HCRU during the 12-month follow up period (Figure 3), the prevalence of ED visits was significantly higher among those with severe epilepsy vs. those with non-severe epilepsy (27% vs. 7%, p < 0.05). Inpatient admissions were also significantly more prevalent among those with severe epilepsy vs. non-severe epilepsy (37% vs. 14%, p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the year following diagnosis, epilepsy-specific inpatient admissions were documented for 12 (20%) and ED visits for 4 (7%) of the 59 individuals with epilepsy (Figure 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aspiration: inpatient admissions at a US Rett center
“Of eligible individuals, 25 (28.1%) were aspiration cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aspiration cases were also significantly twice more likely to have ≥ 1 inpatient admissions for any reason than non-aspiration controls (75.0% vs. 35.0%, p < 0.05). Rates of all-cause outpatient visits and ED visits were similar among the two groups; however, the number of inpatient admissions were higher for the aspiration cases vs. non-aspirating controls (9.4 vs. 2.6, ns), (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Respiratory infection: hospital admissions in an international registry
“A hospital admission for LRTI over the previous 5 years was reported for slightly more than one-fifth (21.4%) of individuals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with independent walking, being unable to walk was associated with a sixfold increased risk (adjusted relative risk 6.73, 95% CI 3.42-13.25), with assisted walking associated with an intermediate risk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Scoliosis surgery: inpatient length of stay and complications in the Kids' Inpatient Database
“Using the International Classification of Diseases Ninth and 10th revision codes in the national Kids' Inpatient Database, we identified children with RTT who underwent PSF from 2000 to 2019.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“RTT diagnosis independently predicted higher odds of any complications (odds ratio: 1.98, P < 0.001) and increased length of stay (odds ratio: 1.18, P = 0.009) for admissions for PSF.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The higher Elixhauser Comorbidity Index in RAS patients predicted higher costs, longer hospital stays, more complications (particularly respiratory), and more nonroutine discharge disposition than in other patients with NMS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Scoliosis surgery: length of stay, readmissions, and reoperations at one US center
“The median estimated blood loss was 600 mL and length of stay was 7 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were 3 readmissions (12%) within 30 days for pneumonia and 2 (8%) reoperations (an incision and drainage and C2-T2 fusion for significant kyphosis) within 90 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic literature review: cost and resource use evidence
Economic impact of Rett syndrome on families
Caregiver employment and caregiving time: 37 UK caregivers
Caregiving time by activity: caregiver diaries in eight European countries
“Care demands were substantial, with caregivers of adults spending an average of 41 hours per week providing emotional support alone, along with high time requirements for feeding (20 hours), washing and bathing (8 hours), and administering medication (5 hours).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Time spent on many caregiving activities was highest in adults, including washing and bathing (7.8 hours per week), feeding (20.3 hours per week), administering medication (5.4 hours per week), helping with physio exercises (5.2 hours per week), and managing the equipment of the patient (4.8 hours per week)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lost employment and out-of-pocket expenses: Canadian patient group input to the trofinetide review
Family strain: TSHA-102 sponsor caregiver survey, 323 caregivers in four countries
“Additionally, caregivers noted the impact of RTT symptoms on themselves (73%, n = 237) and other family members (33%, n = 105), as well as stress and strain on the family overall (52%, n = 167).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Including financial strain, family dynamics, logistics of care, etc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Procedure codes for MECP2 testing
US payer coverage criteria: medical necessity of genetic testing
US laboratory list prices: MECP2 Sanger sequencing at a genetics center
| Field | Quoted record |
|---|---|
| Turnaround time | “21 days” |
| Price | “$900” |
| CPT code | “81302” |
| Method | “This test is performed by Sanger sequencing.” |
| Ordering of deletion/duplication analysis | “Sequencing of the MECP2 gene and MLPA deletion/duplication analysis can be ordered concurrently, sequentially or separately.” |
Next-generation sequencing: effect on turnaround and cost
“A genetic study using NGS allows the study of a larger number of genes associated with RTT-like symptoms simultaneously, providing genetic study of a wider group of patients as well as significantly reducing the response time and cost of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canadian testing costs, turnaround, and out-of-pocket costs: trofinetide reimbursement review
Approaches to treatment
Current treatment options and standard of care
Glycine-Proline-Glutamate analogs
Trofinetide: FDA-approved indication, formulations, and weight-based dosing
| Patient weight | Recommended dosage |
|---|---|
| 9 kg to less than 12 kg | “5,000 mg twice daily” |
| 12 kg to less than 20 kg | “6,000 mg twice daily” |
| 20 kg to less than 35 kg | “8,000 mg twice daily” |
| 35 kg to less than 50 kg | “10,000 mg twice daily” |
| 50 kg or more | “12,000 mg twice daily” |
Trofinetide: class and rationale as a glycine-proline-glutamate analog
“Trofinetide is a synthetic analog of glycine–proline–glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
LAVENDER phase 3 trial: design and co-primary endpoints in the prescribing information
LAVENDER phase 3 trial: co-primary efficacy results at week 12
| Measure | Trofinetide (N=93) | Placebo (N=94) |
|---|---|---|
| RSBQ mean baseline score (SE) | “43.7 (1.21)” | “44.5 (1.26)” |
| RSBQ mean week 12 score (SE) | “39.9 (1.38)” | “42.8 (1.42)” |
| RSBQ LS mean change from baseline to week 12 (SE) | “-4.9 (0.94)” | “-1.7 (0.90)” |
| CGI-I mean week 12 score (SE) | “3.5 (0.08)” | “3.8 (0.06)” |
| Endpoint | Trofinetide-placebo treatment difference, LS mean (95% CI) | p-value |
|---|---|---|
| RSBQ total score change from baseline | “-3.2 (-5.7, -0.6)” | “0.018” |
| CGI-I score at week 12 | “-0.3 (-0.5, -0.1)” | “0.003” |
LAVENDER phase 3 trial: effect sizes, key secondary endpoint, and disposition
“For the coprimary efficacy endpoints, least squares mean (LSM) change from baseline to week 12 in the Rett Syndrome Behaviour Questionnaire for trofinetide versus placebo was −4.9 versus −1.7 (P = 0.0175; Cohen’s d effect size, 0.37), and LSM Clinical Global Impression–Improvement at week 12 was 3.5 versus 3.8 (P = 0.0030; effect size, 0.47).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the key secondary efficacy endpoint, LSM change from baseline to week 12 in the Communication and Symbolic Behavior Scales Developmental Profile Infant–Toddler Checklist Social Composite score was −0.1 versus −1.1 (P = 0.0064; effect size, 0.43).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“155 participants (82.9%) completed the study (trofinetide, n = 70 (75.3%); placebo, n = 85 (90.4%))” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eighteen participants withdrew due to a TEAE (trofinetide, n = 16 (17.2%); placebo, n = 2 (2.1%)), with diarrhea being the primary TEAE leading to discontinuation (trofinetide, n = 12 (12.9%))” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trofinetide: warnings for diarrhea, weight loss, and vomiting
LILAC open-label extension: 40-week safety and efficacy
“Females with Rett syndrome aged 5-21 years received open-label treatment with trofinetide for 40 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 154 participants were enrolled and treated with trofinetide in LILAC. The most common adverse events in LILAC were diarrhea (74.7%), vomiting (28.6%), and COVID-19 (11.0%). Diarrhea was the most common adverse event leading to treatment withdrawal (21.4%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The Rett Syndrome Behaviour Questionnaire mean score (standard error) improvement from the LAVENDER baseline to week 40 in LILAC was -7.3 (1.62) and -7.0 (1.61) for participants treated with trofinetide and placebo in LAVENDER, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LILAC-2 open-label extension: 32-month safety and efficacy
“In total, 77 participants were enrolled in LILAC-2. The most common AEs were diarrhea (53.2%), COVID-19 (27.3%), and vomiting (19.5%). The mean (standard error [SE]) change in RSBQ score from LAVENDER baseline to week 104 of LILAC-2 was -11.8 (2.45).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most caregivers (96%; n = 24/25) were satisfied or very satisfied with the benefits of trofinetide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
DAFFODIL open-label study: girls aged 2 to 4 years
“DAFFODIL was a phase 2/3, open-label study of trofinetide consisting of two treatment periods (12 weeks [period A] and ∼21 months [period B]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen participants were enrolled. Overall, the most common TEAEs were diarrhea (80.0%) and vomiting (53.3%), which were mild or moderate in severity. Steady-state exposure at clinical doses fell within the target exposure range.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LOTUS real-world study: dosing, caregiver-reported benefit, and diarrhea
“Overall, 227 caregivers participated in this follow‐up. The median trofinetide dose at week 1 was 36.0% of the target dose and increased to over 80% by week 10 onwards; 55.2% of patients took the full trofinetide recommended daily dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of diarrhea varied from weeks 1 to 12 (23%–50%) and months 4 to 12 (26%–38%); most reports of diarrhea were contained inside the patient's diaper.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expert consensus: trofinetide as first-line therapy and titration
“Two rounds of assessments were completed by 25 respondents in each round, resulting in agreement ≥ 75% being reached across the final statement set. The consensus supports trofinetide as the standard of care for eligible patients with early initiation and an individualized approach to titration to maximize efficacy and tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Agreement (88%–100%) across statements 1–2 and 5–7 supports trofinetide as first‐line therapy in the standard of care for eligible patients with RTT aged ≥ 2 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To minimize the impact of side effects, this consensus supports initiation at 5–10 mL (1000–2000 mg) BID or 25%–50% of the recommended weight‐banded dose BID and then titrate carefully at 5 mL (1000 mg) increase every 1–2 weeks based on tolerance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents supported maintaining treatment with trofinetide for at least 6 months post titration to determine efficacy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expert consensus: selected statements and overall agreement
European Union authorization: neurobehavioural symptoms, age 5 years and older
Antiseizure medications
Consensus guideline: neurology referral and antiseizure medication monitoring
“Refer to neurologist for seizures and spells suspicious for seizures, with follow-up every 6 months if treated with an anticonvulsant. It is difficult to differentiate between a non-epileptic Rett spell and a seizure (both may be present).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If the individual’s weight fluctuates (more than 10%–20%), request the neurologist to consider adjusting anticonvulsant doses accordingly. Laboratory follow-up as needed for use of antiseizure medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“but there have been no randomised controlled trials of specific anticonvulsants for RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural History Study: remission and medication withdrawal
“Although 248 of those with classic Rett syndrome and a history of seizures were in terminal remission at last contact, only 74 (12% of those with a history of epilepsy) were seizure free and off anti-seizure medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, persistent drug resistant epilepsy without remission is not the most common pattern, only affecting 16% of those with classic Rett syndrome, a figure less than half that of the Italian and Australian studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antiseizure drug selection: comparative evidence and adverse-effect considerations
“Although cases and retrospective studies document efficacy of specific medications in Rett syndrome, no systematic study has demonstrated superiority of a specific medication or class of medications to treat epilepsy in Rett syndrome” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No specific medications are contraindicated in Rett syndrome; however, the issue of bone health is an important consideration when prescribing anti-seizure drugs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In summary, when seizures are concluded to be epileptic in origin and anti-seizure drugs are initiated, the side effect profiles of medications should be considered carefully, and medications, which can cause behavioural issues (e.g. levetiracetam), anorexia and nephrolithiasis (e.g. topiramate), QT interval prolongation (e.g. felbamate), or marked sedation (e.g. benzodiazepines), should be used with caution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Review: lack of comparative studies and non-pharmacological options for refractory epilepsy
“There are problems in evaluating the treatment efficiency of AED due to the general lack of comparative studies and the number of different AED used in monotherapy or combination treatment in RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to limited experience of epilepsy treatment in RTT, no definite recommendation regarding anticonvulsants is currently available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ketogenic diet and vagal nerve stimulation have been reported to be effective treatment options in some refractory RTT cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antiseizure medications prescribed in a US electronic health record cohort
| Antiseizure medication | Participants with epilepsy, n (%) (N = 59) |
|---|---|
| Levetiracetam | “27 (45.8%)”View highlighted excerpt for this quote |
| Clonazepam | “22 (37.3%)”View highlighted excerpt for this quote |
| Oxcarbazepine | “18 (30.5%)”View highlighted excerpt for this quote |
| Lamotrigine | “15 (25.4%)”View highlighted excerpt for this quote |
| Valproate or valproic acid | “15 (25.4%)”View highlighted excerpt for this quote |
| Topiramate | “10 (16.9%)”View highlighted excerpt for this quote |
| Lacosamide | “7 (11.9%)”View highlighted excerpt for this quote |
Drug-resistant epilepsy and absence of first-line recommendations
“While AEDs are effective therapy, either as monotherapy or in combination, for many individuals who have seizures in RTT, 20–40% experience drug-resistant epilepsy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the non-localized nature of epilepsy in RTT, unlike individuals with other types epilepsy (i.e., focal onset epilepsy), surgical treatments are generally not effective for drug-resistant epilepsy in RTT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cannabidiol for drug-resistant epilepsy: Italian multicenter cohort
“We enrolled 27 subjects (26 females), carrying a MECP2 genetic variant (14 subjects, 51.9%) or a CDKL5 genetic variant (13 subjects, 48.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although not reaching a significant statistical effect, CBD reduced the incidence of seizures with respect to the baseline in 18/27 (66.6%) subjects, with 7 (25.9%) showing a seizure reduction >75%, and 11 (40.7%) >50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most relevant adverse events were somnolence seen in 3 subjects, irritability/agitation in 2 subjects, loss of appetite in 2 subjects, and insomnia in 1 individual.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cannabidiol as adjunctive therapy: French single-center cohort
“In our cohort, 26 patients had associated epilepsy (26/46 [56%]), and 10/26 (38%) were treated with CBD, in combination with clobazam in 50% of cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CBD reduced the incidence of seizures in seven out of 10 patients (70%) with one seizure‐free patient, two patients with a reduction of seizures of more than 75%, and four patients with a decrease of more than 50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rescue therapy: diazepam nasal spray for seizure clusters
“Age- and weight-based doses of diazepam nasal spray (5–20 mg) were administered to patients (aged 6–65 years) for seizure clusters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All caregivers felt diazepam nasal spray was very/extremely easy to use; 63.6% were able to return to normal activities within an hour of administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diazepam nasal spray has safety and effectiveness profiles consistent with the full study population and was easy to use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trofinetide with concomitant antiseizure medication
“The most frequently used concomitant medications in the trofinetide and placebo groups were antiseizure medication (64.5% and 72.3%, respectively) and drugs for constipation (60.2% and 70.2%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patient history of seizures should be taken prior to initiating trofinetide, if possible” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the majority will not experience changes in seizures, while the minority may experience improvement or worsening during treatment, depending on the individual patient” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gastrointestinal and nutritional management
Consensus guideline: constipation and gastro-oesophageal reflux
“Laxatives (polyethylene glycol, magnesium hydroxide, glycerin or bisacodyl suppositories) are often part of long-term treatment with a goal of one soft bowel movement per day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Proton pump inhibitor or H2 blockers are used empirically. Referral to gastroenterologist may be necessary to rule out complications such as oesophagitis, ulcer, strictures or Barrett’s oesophagus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gall bladder dysfunction, screened by abdominal ultrasound, should be considered. Referral to surgery for cholecystectomy may be necessary for symptomatic gallstones or biliary dyskinesia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus guideline: poor weight gain, prolonged feeding, and swallowing difficulties
“Fatigue and irritability may be signs that dietary requirements are not being met; consider energy dense foods (oils, syrups, avocado), and gastroenterologist and nutrition consults. Gastrostomy button may be needed to maintain growth; counsel families that use of a gastrostomy button does not preclude oral feeding as long as oral feeding is safe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Long feeding times (more than 30 min) can affect quality of life for patient and family; this may be an indication that a gastrostomy button is needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In some cases, thickeners for liquids may be helpful to prevent aspiration versus need for a gastrostomy button.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consider nutrition-related laboratory screening (yearly): complete blood count, electrolyte panel, 25-OH vitamin D, fasting lipids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expert recommendations: proactive management of gastrointestinal comorbidities
“Although gastrointestinal (GI) comorbidities are experienced by over 90% of individuals with Rett syndrome (RTT), a neurodevelopmental disorder associated with mutations in the MECP2 gene, many neurologists and pediatricians do not rank the management of these comorbidities among the most important treatment goals for RTT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The authors recommend a proactive approach to management of symptomatic GI comorbidities and drug-associated symptoms in RTT to enhance drug tolerance and improve the quality of life of affected individuals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world management by US physicians: constipation, growth, and reflux
“For the treatment of constipation, neurologists most commonly referred patients to a dietician or to a gastroenterologist (57.1% each), while pediatricians were most likely to provide dietary recommendation (91.3%), refer to a dietician (78.3%), and prescribe laxatives (69.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 10 pediatricians who responded, all (100%) prescribed anti-reflux medication, 8 (80%) referred to a dietician, and 7 (70%) provided dietary recommendations and advice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Management of GI issues was ranked among the five most important treatment goals by 3 (5.9%) neurologists and 4 (8.2%) pediatricians surveyed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gastrostomy: utilization, weight gain, and family satisfaction in an Australian population cohort
“Sixty-six females (28.8%) had a gastrostomy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight-for-age z-scores increased by 0.86 (95% CI 0.41, 1.31) approximately 2 years after surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Families were satisfied with gastrostomy and felt less anxious about the care of their child.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gastrostomy: body mass index and mortality in a longitudinal cohort
“Nearly one-third (30.3%) of the cases underwent gastrostomy placement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, among those at risk of suboptimal weight, the all-cause mortality rate was greater in those who had gastrostomy placement compared with those who had not (hazard ratio 4.07, 95% CI 1.96-8.45).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrostomy placement was associated with improvement in BMI in females with Rett syndrome, but its long-term impact on individuals and their families is unclear.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Multidisciplinary clinic cohort: aperients and gastrostomy
“Constipation was reported in 65% and all required specific treatment with aperients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrostomy feeding tube placement was required for 24 (23.3%) girls at a mean age of 8 years (SD 4.2 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review: enteral feeding utilization across studies
Scoliosis management and spinal surgery
Consensus guideline: surveillance and referral thresholds
“Increased risk of neuromuscular scoliosis after age 6; risk typically abates after puberty. This can progress rapidly if present, necessitating reobservation every 6 months if present. Supine X-ray and orthopaedic referral when scoliotic curvature greater than 20°; correction may be indicated when greater than 40°.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Surveillance for scoliosis becomes an important preventive measure; some children (~20%) ultimately require spinal surgery for this comorbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus guideline: scoliosis management across the lifespan
“The second draft comprised 88 items with agreement to strong agreement achieved on 85, to form the final guideline document.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A comprehensive, life-span approach to the management of scoliosis in Rett syndrome is recommended that takes into account factors such as physical activity, posture, nutritional and bone health needs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Surgery should be considered when the Cobb angle is approximately 40 degrees to 50 degrees and must be supported by specialist management of anesthesia, pain control, seizures, and early mobilization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Natural History Study: frequency of surgery and recommendations for bracing and surgery
“913 females with classic RTT were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“168 (18%) had surgical correction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of the actual age distribution for the 168 participants who had surgical correction, the majority (86%) occurred between age 9 and 15, the median age was 12 years (min=5, max=21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As such, when curves reach 25°, we recommend implementation of bracing in hopes of retarding or minimizing further progression. However, once the curve reaches 40° or more, we strongly promote surgical intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Spinal fusion and survival in severe scoliosis
“After adjusting for mutation type and age of scoliosis onset, the rate of death was lower in the surgery group (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.12-0.74; p=0.009) compared to those without surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With appropriate cautions, spinal fusion confers an advantage to life expectancy in Rett syndrome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
US national trends and perioperative outcomes of posterior spinal fusion
“Among 220 patients with RAS, 216 (98.2%) were females (mean age at surgery: 12.3±3.3 yr).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“RTT diagnosis independently predicted higher odds of any complications (odds ratio: 1.98, P < 0.001) and increased length of stay (odds ratio: 1.18, P = 0.009) for admissions for PSF.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Surgical treatment for RAS is rare but increased over a 19-year period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Growth-friendly surgery and posterior spinal fusion in early onset scoliosis
“The study included 15 females with Rett syndrome. Five patients had MCGR and 10 underwent PSF.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was one complication per group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both MCGR and PSF effectively control scoliosis in RS patients. PSF provides superior coronal curve correction, while MCGR promotes spinal growth.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Orthotics and timing of spinal fusion
Multidisciplinary clinic cohort and systematic review: rates of scoliosis surgery
Bone health management
Consensus guideline: fracture risk, densitometry, calcium, and vitamin D
“There is higher risk of fracture due to immobility and use of anticonvulsants. If fracture occurs, consider bone density (DEXA) scan and referral to endocrine specialist (in addition to aggressive screen of calcium, vitamin D intake and 25-OH vitamin D levels).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ensure supplemental vitamin D intake: 600–1000 IU or more daily. Target serum levels of 25-OH-vitamin D greater than 30–40 ng/mL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With age, concern for low bone mineral mass coupled with long-term use of particular anticonvulsants raises the risks for osteoporosis and bone fractures” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bone health guideline: assessment and first-line interventions
“Agreement was reached on 39 statements which were formulated from 41 statements and 11 questions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A baseline densitometry assessment should be performed with accommodations made for size, with the frequency of surveillance determined according to individual risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing physical activity and initiating calcium and vitamin D supplementation when low are the first approaches to optimizing bone health in Rett syndrome. If individuals with Rett syndrome meet the ISCD criterion for osteoporosis in children, the use of bisphosphonates is recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bone health guideline: non-pharmacological and pharmacological statements with panel agreement
Bone health guideline: limited evidence for bisphosphonates
“Whilst the group agreed that bisphosphonate therapy may be indicated, several panel members did make note of the lack of evidence for efficacy and safety of bisphosphonate use in RTT and that its mechanism of action may be different from disorders such as osteogenesis imperfecta in which its use is frequent” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zoledronate: retrospective national center cohort
“Nine patients (23%) received zoledronate, for a mean 2 years. The mean age at zoledronate initiation was 9.7 ± 2.3 years. Four completed two DXA scans (pre- and post-treatment); the mean BMD Z-score improved from −2.2 ± 0.9 to −1.4 ± 0.9 after treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Poor L1–4 BMD Z-scores were associated with poor mobility scores (p = 0.05) and valproate treatment (p = 0.016).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zoledronic acid: annual infusion in children with cerebral palsy and Rett syndrome
“27 children under 18 years (19 with cerebral palsy and 8 girls with Rett syndrome confirmed by MCEP2 mutation) were treated with an annual injection of 0.1 mg/kg (max 4 mg) of ZA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No fractures have been observed in our cohort since the first infusion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Side effects (flu-like syndrome and hypocalcemia) were more common in younger patients and after the first infusion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychotropic medications for anxiety and behavior
Consensus guideline: screening for anxiety and depression and selective serotonin reuptake inhibitors
“Screen for caregiver impressions of anxiety and depression, such as withdrawal; these may become more prominent with age or in individuals with milder clinical presentations. Identify possible contributors (eg, sedating medications, decreased social interaction, limited access to engaging activities). Consider treatment with a selective serotonin reuptake inhibitor such as escitalopram which may have a lower risk of inducing a prolonged QTc interval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Families should be encouraged to disclose use of alternative medications (cannabis, oils and so on) to all specialists.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural History Study: absence of anxiety management guidelines
“In spite of the general impression that anxiety-like behavior is common in individuals with RTT, no systematic studies of anxiolytics use have been reported in this population and guidelines for clinical management of anxiety in RTT do not exist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural History Study: frequency of anxiolytic and SSRI use
“Parental reports and medication logs provided data from 1380 females with RTT participating in two iterations of the multicenter U.S. RTT Natural History Study (RNHS) from 2006 to 2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Parents directly reported treatment for anxious or nervous behavior in 16.6% of participants in the second iteration with most reporting good control of the behavior (71.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“15.0% of participants in the first and 14.5% in the second (P = 0.835). The most commonly used drugs were escitalopram, sertraline, fluoxetine, and buspirone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on medication logs, SSRI use for any indication was reported for 13.1% of participants in the first iteration and 11.0% in the second iteration (P = 0.414).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increased use of anxiolytics and selective serotonin reuptake inhibitors (SSRIs) was related to more frequent anxiety-like behaviors (P < 0.001), older age (P < 0.001), and mild MECP2 variants (P = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural History Study: efficacy and safety not assessed
Sleep management
Consensus guideline: melatonin, trazodone, clonidine, bed safety, iron, and sleep study
“Circadian rhythm is often disrupted; consider melatonin to initiate sleep and trazodone or clonidine to maintain asleep. Patient may be getting out of bed, which could be unsafe; consider a tent-style bed or similar engineering controls to keep child in bed and safe. Consider ferritin, serum iron, total iron binding capacity and transferrin levels if there is disrupted sleep or concerns for restless leg syndrome and need for iron replacement. Consider overnight sleep study for snoring or pauses in breathing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sleep hygiene and medication use: International Rett Syndrome Phenotype Database
“Sleep disturbances are debilitating for individuals with Rett syndrome (RTT) and their families yet the evidence base for management is poor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Data were provided by 364/461 (79%) families with a child with RTT and registered with the International RTT Phenotype Database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Better use of sleep hygiene practices was associated with lower odds of moderate/major impact on the family (odds ratio 0.60, 95% confidence intervals [CIs] 0.37, 0.98) and lower DIMS scores (geometric mean ratio 0.86, 95%CI 0.80, 0.92) compared with poorer use after adjusting for covariates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Attention to sleep hygiene remains an important management strategy for sleep problems in RTT. Further prospective research is required to investigate efficacy of pharmaceutical treatments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Melatonin: double-blind, placebo-controlled crossover trial
“Subsequently, patients underwent a 4-week melatonin treatment period in a double-blind, placebo-controlled, crossover protocol that employed a 1-week washout between treatment trials. Melatonin doses ranged from 2.5 to 7.5 mg, based upon individual body weight.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Melatonin significantly decreased sleep-onset latency to (mean +/- SE) 19.1+/-5.3 minutes (P<0.05) during the first 3 weeks of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, a 4-week administration of melatonin appears to be a safe treatment as no adverse side effects were detected, yet long-term effects of chronic melatonin use in pediatric patients are unknown at this time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Multidisciplinary clinic cohort: sleep medications prescribed
“Melatonin was the most common medication prescribed in our cohort and is most helpful for sleep initiation [28]. Other medications commonly prescribed for management of sleep disturbance included clonidine, chloral hydrate, Phenergan and risperidone [28].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obstructive sleep apnea on polysomnography and screening
“Six of thirteen participants had obstructive sleep apnea, which was worse during rapid eye movement (REM) sleep with associated hypoxemia and disruptions in sleep architecture.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This suggests that providers should routinely screen for sleep problems and implement interventions that can positively impact the quality of life of individuals with Rett syndrome and their families.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Narrative review: sleep hygiene as first-line therapy
“Evidence on management of sleep disorders is lacking, as no algorithms are available, the choice of therapy depends on each case (15, 95).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To date, sleep hygiene remains the first-line therapy. Although melatonin has been shown to be effective in improving total sleep time and sleep onset latency, the literature on drug efficacy and safety is poor and drug trials need to be designed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rehabilitative and communication therapies
Consensus guideline: therapies to maintain and regain skills
“Skills can be maintained and possibly regained with vigorous therapies. Therapies to consider: speech therapy, feeding therapy, occupational therapy, augmentative communication therapy, vision therapy, hippotherapy (horse) and swim/pool therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therapies for RTT should include occupational, physical, speech, swallowing and augmentative communication. Therapy that maximises physical activities should be lifelong, as these will minimise long-term complications and maximise long-term potentials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consider occupational therapy (OT) and physical therapy (PT) consults for bracing and splinting. Consider neurology and physiatry consults for neuromuscular blockade or other medications to improve tone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus guideline: augmentative and alternative communication and eye gaze devices
“Alternative and augmentative communication assessments are needed. While this can be done by some speech therapists, a specific referral may be needed. Since eye gaze is typically the most effective form of communication, special eye gaze devices can give individuals a voice. These referrals should be made as early as possible to coincide with typical language development.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Communication guideline: international Delphi consensus
“All statements that reached a pre-determined threshold of ≥70% agreement were incorporated into guidelines that consist of 268 statements and recommendations relating to (a) rights of the individual; (b) beliefs and attitudes of communication partners; (c) professional knowledge and team work; (d) strategies to optimize engagement; (e) assessment; and (f) intervention (targets and goals, techniques), including the use of AAC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To date, this project is the largest of its kind, with 650 participants from 43 countries contributing to development of consensus-based guidelines for Rett syndrome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review: communication intervention studies, 2010 to 2022
“Across the 16 studies, intervention was provided to a total of 100 participants from 3 to 47 years of age. Half of the studies used systematic instruction to teach aided AAC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Positive outcomes (e.g., using AAC devices to make requests and/or initiate social-communication interactions) were reported in 13 of the studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Eye gaze technology: family experiences in the Netherlands
“20 respondents were using or had previous experience of using an eye gaze system at the time of the survey, 28 of those with no prior experience wanted to try a system in the future. Following a trial period, 11 systems had been funded through health insurance for long-term use and two families had decided a system was not appropriate for them.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of families reported progress in their child’s skills with longer term use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Environmental enrichment: individually randomised stepped wedge trial
“A genetically variable group of 12 girls with a MECP2 mutation and younger than 6 years participated in a modified individually randomised stepped wedge design study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The intervention comprised motor learning and exercise supplemented with social, cognitive and other sensory experiences over a six-month period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusting for covariates, the enriched environment was associated with improved gross motor skills (coefficient 8.2, 95%CI 5.1, 11.2) and a 321.4 ng/ml (95%CI 272.0, 370.8) increase in blood BDNF levels after 6 months of treatment. Growth, sleep quality and mood were unaffected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review: physical therapy approaches
“Nine approaches to physical therapy for patients with Rett syndrome were identified: applied behavior analysis, conductive education, environmental enrichment, traditional physiotherapy with or without aids, hydrotherapy, treadmill, music therapy, computerized systems, and sensory-based treatment. It has been reported that patients had clinically benefited from the analysed approaches despite the fact that they did not have strong research evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review: utilization of physical, occupational, and speech therapy
“Six studies examined ancillary service use, where PT utilization ranged from 24.4% to 100.0% and occupational therapy (OT) ranged from 11.5% to 91.7%. Pediatric patients demonstrated a two- to fourfold higher utilization of PT and OT services compared to adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The two US-based retrospective claims analyses reported ST utilization rates of 74.1% and 13.3%, respectively [4, 11].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, rehabilitation therapies such as PT, OT, and ST are commonly recommended as part of supportive management based on functional needs, but there is little RTT-specific evidence to define whether ongoing, episodic, intensive, or consultative therapy models are optimal at different ages [12, 37].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary: what current options treat
- Trofinetide is indicated in the United States for Rett syndrome in adults and pediatric patients 2 years of age and older, and its mechanism of action in Rett syndrome is unknown. An expert consensus of 25 respondents supports it as first-line therapy for eligible patients aged 2 years or older. The European Union authorization covers the neurobehavioural symptoms of Rett syndrome in patients aged 5 years and older.
- The other options described in the sources address individual comorbidities: antiseizure medications for seizures; laxatives, acid suppression, and gastrostomy for gastrointestinal and nutritional problems; bracing and spinal surgery for scoliosis; physical activity, calcium, vitamin D, and bisphosphonates for bone health; selective serotonin reuptake inhibitors for anxiety; melatonin, trazodone, or clonidine for sleep; and physical, occupational, speech, and augmentative communication therapies.
Summary: size of the trofinetide effect
- In the 12-week randomized, double-blind, placebo-controlled study that established efficacy (Study 1 in the prescribing information), participants aged 5 to 20 years were randomized to trofinetide (N=93) or placebo (N=94). The least squares mean change in RSBQ total score was -4.9 with trofinetide and -1.7 with placebo, a difference of -3.2 (95% CI -5.7 to -0.6; p = 0.018; Cohen's d effect size 0.37). The mean CGI-I score at week 12 was 3.5 against 3.8, a difference of -0.3 (95% CI -0.5 to -0.1; p = 0.003; effect size 0.47). The key secondary endpoint, the Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist Social Composite score, changed by -0.1 against -1.1 (P = 0.0064; effect size 0.43).
- The European Medicines Agency described the improvements as small and considered them relevant for a rare and serious disorder.
- In open-label extensions, the mean RSBQ improvement from the LAVENDER baseline was -7.3 (1.62) and -7.0 (1.61) at week 40 of LILAC (154 participants) for those given trofinetide and placebo in LAVENDER, and -11.8 (2.45) at week 104 of LILAC-2 (77 participants).
Summary: trofinetide tolerability and discontinuation
- In Study 1, diarrhea occurred in 82% of participants receiving trofinetide and 20% receiving placebo, and vomiting in 29% and 12%. Across Study 1 and long-term studies, 85% of trofinetide-treated patients had diarrhea, and 49% had persistent or recurrent diarrhea despite dose interruptions, reductions, or antidiarrheal therapy; 51% used antidiarrheal medication in Study 1. Weight loss greater than 7% occurred in 12% receiving trofinetide and 4% receiving placebo in Study 1, and 2.2% discontinued for weight loss in long-term studies. Aspiration and aspiration pneumonia have been reported after vomiting.
- The two sources give different withdrawal counts for the 12-week study: the prescribing information reports 18 patients (19%) receiving trofinetide who withdrew because of adverse reactions, most often diarrhea (15%), and the trial publication reports 16 (17.2%) receiving trofinetide and 2 (2.1%) receiving placebo who withdrew because of a treatment-emergent adverse event, with diarrhea leading to discontinuation in 12 (12.9%). The study was completed by 70 (75.3%) participants receiving trofinetide and 85 (90.4%) receiving placebo.
- In LILAC, diarrhea occurred in 74.7% and was the most common adverse event leading to withdrawal (21.4%). In a follow-up of 227 caregivers, the median dose at week 1 was 36.0% of the target dose, rising to over 80% from week 10, 55.2% of patients took the full recommended daily dose, and diarrhea incidence ranged from 23% to 50% during weeks 1 to 12. The expert consensus recommends starting at 25% to 50% of the weight-banded dose and titrating every 1 to 2 weeks.
Summary: age range of trofinetide evidence
- The randomized evidence comes from participants aged 5 to 20 years, and LILAC enrolled females aged 5 to 21 years. Use in patients aged 2 to 4 years is supported by the randomized study together with pharmacokinetic and safety data in 15 patients aged 2 to 4 years. The open-label DAFFODIL study enrolled 15 participants, in whom diarrhea occurred in 80.0% and vomiting in 53.3%. Safety and effectiveness below 2 years of age have not been established, and the European Union authorization applies from 5 years of age.
- In natural history data, regression began between 12 and 30 months of age in more than 80% of individuals, and the median age of skill loss was 3 years or younger for 46 of 51 developmental skills.
Summary: evidence gaps in supportive care
- Epilepsy: no randomised controlled trials of specific anticonvulsants have been conducted in Rett syndrome, no systematic study has shown one medication or class to be superior, and no definite recommendation is available. Drug-resistant epilepsy affects 20% to 40% of those with seizures, and surgical treatment is generally ineffective. Of those with classic Rett syndrome and a history of epilepsy in one cohort, 74 (12%) were seizure free and off antiseizure medication at last contact. In a cohort of 27 subjects carrying an MECP2 (14) or CDKL5 (13) variant, cannabidiol reduced seizures in 18 of 27 (66.6%) without reaching statistical significance.
- Gastrointestinal and nutrition: 3 (5.9%) neurologists and 4 (8.2%) pediatricians surveyed ranked gastrointestinal management among their five most important treatment goals. Among individuals at risk of suboptimal weight, all-cause mortality was higher after gastrostomy placement (hazard ratio 4.07, 95% CI 1.96 to 8.45), and its long-term impact is described as unclear.
- Scoliosis: scoliosis often does not respond to orthotics. A Rett syndrome diagnosis predicted higher odds of complications (odds ratio 1.98) in admissions for posterior spinal fusion, and the rate of death was lower in those who had scoliosis surgery than in those without surgery (hazard ratio 0.30, 95% CI 0.12 to 0.74).
- Bone health: panel members noted the lack of evidence for the efficacy and safety of bisphosphonates in Rett syndrome, and the bisphosphonate indication statement reached 17/23 (73.9) agreement.
- Anxiety and sleep: no systematic studies of anxiolytics and no anxiety management guidelines exist, and the Natural History Study was not designed to assess their efficacy or safety. Sleep management has no treatment algorithm. In a 4-week double-blind, placebo-controlled crossover trial of melatonin, sleep-onset latency decreased to 19.1 (SE 5.3) minutes during the first 3 weeks, and the long-term effects of chronic use in pediatric patients are unknown.
- Rehabilitation: one publication identified nine physical therapy approaches and reported clinical benefit from them despite an absence of strong research evidence. Across 16 communication intervention studies, intervention was provided to a total of 100 participants. Little evidence specific to Rett syndrome defines whether ongoing, episodic, intensive, or consultative therapy models are optimal at different ages.
Place in treatment, anticipated use, and care setting
Anticipated population: patients aged 2 years and older
Care setting: one-time outpatient intrathecal administration
Payer research: value proposition of a one-time outpatient administration
Route of administration: intrathecal lumbar compared with intracerebroventricular delivery
“Administration route strongly influences biodistribution: ICV delivery (NGN-401) provides broad brain penetration but requires neurosurgery, whereas intrathecal lumbar injection (TSHA-102) is less invasive but may yield more limited forebrain distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ICV delivery requires neurosurgical placement of a catheter into the lateral ventricle” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role of neurologists and specialized centers
“As these therapies progress toward potential regulatory approval, neurologists will play central roles in identifying eligible patients, counseling families, supporting clinical trial enrollment, delivering treatments, monitoring long-term outcomes, and advocating for equitable access.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Access is further constrained by the need for specialized centers capable of administering therapy and monitoring for complications, disproportionately affecting families in rural areas, underserved communities, and low-income countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
REVEAL Part A: response across age, disease severity, and genotype
REVEAL Part A: response by dose cohort
Published review: dose response in the first REVEAL cohorts
MECP2 variant: genotype coverage of the miniMECP2 transgene
“By delivering the essential MBD and NID functional domains, TSHA-102 provides a genotype-agnostic approach that encompasses the molecular defects found in over 95% of the RTT population, including the eight most common recurrent mutations and nearly all pathogenic missense variants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MECP2 variant and X-chromosome inactivation: sources of variation in disease severity
“Thus, we have confirmed that MECP2 mutation type is a strong predictor of disease severity. However, clinical severity continues to become progressively worse with advancing age regardless of initial severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because the MECP2 gene is subject to X‐chromosome inactivation (XCI), factors including MECP2 genotypic variation, tissue differences in XCI, and skewing of XCI all likely contribute to the clinical severity of individuals with RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at treatment: developmental window
“Nonetheless, several considerations favor earlier intervention: the first 2–3 years of life represent critical windows of synaptogenesis and circuit formation; prolonged MeCP2 deficiency may lead to structural neuronal and glial changes that become harder to reverse; and treating before or during early regression could prevent milestone loss rather than requiring later recovery (83, 84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ultimately, a stratified approach may emerge in which early treatment maximizes developmental potential while older individuals are treated to achieve meaningful functional gains.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at treatment: spontaneous milestone gain before 6 years of age in natural history
Children aged 2 to less than 6 years: efficacy extrapolated from older participants
Care management intervention strategies
Consensus guideline: multispecialty care coordinated through a primary care checklist
“Management of RTT requires input or expertise related to multiple specialties, often necessitating referrals to many providers in addition to the primary care provider.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The checklist (table 1) is suitable for use by health professionals as well as the family as part of their healthcare records, with tables 2–6 providing further detailed guidance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Review available community and insurance resources (disabled parking permit, respite care and so on).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus guideline: hospitalisation and anaesthesia precautions
“Individuals may be more sensitive to effects of anaesthetics. They may take longer to awaken from anaesthesia. It is important to ensure anaesthesiologist is aware of current medications (especially anticonvulsants and cannabis preparations), type and description of seizures, breathing abnormalities, and risk of presence of prolonged QTc; a recent ECG is essential.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anaesthesia recommendation: postoperative respiratory care
Respiratory management: Italian Delphi consensus
“Noninvasive ventilation should be considered in all RS subjects with sleep respiratory disorders and in those with hypotonia associated with hypercapnia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Chest physiotherapy should be performed in all RS patients with difficult management of the accumulation of respiratory secretions, using airway clearance techniques and devices (PEP-mask, AMBU bag, or cough machine), more appropriate and tolerated by the patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Multidisciplinary clinic model: 20 years at a pediatric tertiary hospital
“The clinic has a diverse team of medical practitioners, including a Pediatrician, Clinical Geneticist and Dentist, along with Allied Health professionals such as a Genetic Counsellor, Dietitian, Physiotherapist, Occupational Therapist, Speech Therapist and a Music Therapist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The results of this study highlight the usefulness of our clinical model based on multidisciplinary management aimed at preserving and/or prolonging independence in mobility, feeding and communication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transition from paediatric to adult care
“We have a formal programme for transition and transfer of care that takes into account external referrals and ensures continuity of care for those paediatric individuals who are already known to our staff.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The delineation of an adult phenotype in Rett syndrome demonstrates the importance of a transitional programme and the need of a dedicated multidisciplinary team to optimise the clinical management of these patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fragmented care: European caregiver study
“87% of participants reported having to change their primary physician, with the most common reported reasons including dissatisfaction with care (15%), inadequate follow-up or coordination of care (15%), and evolving needs (17%) (Fig. 5e). Only 3% of RTT patients access a sleep specialist, despite sleep being a highly disruptive issue.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Care was also reported to be geographically fragmented with only 3% of participants reporting that they received all their care at the same location” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The changing needs across the lifespan underscore the importance of anticipatory, multidisciplinary care models and improved transition pathways into adulthood.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver education for trofinetide gastrointestinal adverse events
“The nurse coordinators emphasized the importance of participant/caregiver education when introducing a new drug, and their experiences with the GI side effects of trofinetide in the LAVENDER trial informed their communications with the caregivers. A common theme is that, although there are some strategies for managing GI side effects that should be recommended initially (e.g., loperamide for diarrhea), each individual with RTT is unique and different methods may work better in some than others.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
FDA post-marketing obligations
No evidence found.
Data required by the FDA for inclusion in the planned submission
Paediatric investigation plan agreed by the European Medicines Agency
Ongoing post-approval monitoring
Post-approval monitoring commitments for TSHA-102
No evidence found.
Requirements that would apply after approval
Continued monitoring of treated participants in the clinical trials
Expected outcomes of therapy
Sponsor-stated goal: one-time treatment of the genetic cause
Pivotal efficacy threshold: developmental milestone response rate
REVEAL Part A: functional gains over 12 or more months
Caregiver-defined meaningful outcomes of gene therapy
Uncertainty: durability, long-term safety, and clinically meaningful benefit
“Determining what constitutes clinically meaningful benefit is equally difficult; families report that even modest gains in independence, communication, or daily living skills are profoundly valuable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because gene therapy aims to deliver lifelong MeCP2 expression, long-term safety remains largely unknown. Open questions include durability of expression, feasibility of re-dosing in the context of anti-AAV immunity, potential for delayed toxicity from MeCP2 overexpression, risk of chronic CNS immune responses, and the theoretical possibility of insertional mutagenesis despite low AAV integration rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Addressing these uncertainties will require decades-long surveillance; current protocols mandate 15-year follow-up for all treated individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote